Chimeric Antigen Receptor T Cell Therapy for Glioblastoma: Clinical Advances and Emerging Strategies.

Authors

Eric P Grewal, Rishab Ramapriyan, William T Curry, Bryan D Choi

Published in

Hematology/oncology clinics of North America. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

Chimeric antigen receptor (CAR) T cell therapy is a promising investigational modality for glioblastoma (GBM), but durable disease control has been limited by antigen heterogeneity, adaptive resistance, and an immunosuppressive tumor microenvironment. Early phase I studies targeting IL-13Rα2, HER2, EGFRvIII, EphA2, B7-H3, and GD2 established proof-of-concept for CAR T cell therapy in recurrent GBM and provided important clinical insights regarding feasibility, safety, and resistance mechanisms. More recent approaches, including multi-antigen targeting and locoregional delivery, aim to address these limitations, and ongoing trials evaluating new antigens and engineered platforms may further expand the clinical potential of CAR T cells in GBM.

PMID:
42816201
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.